Scott Douglas Hansen

US Patent:

20040234953, Nov 25, 2004

Filed:

Feb 12, 2004

Appl. No.:

10/779597

Inventors:

Scott Wong - Beaverton OR, US
Michael Axthelm - Hillsboro OR, US
Scott Hansen - Hillsboro OR, US

Assignee:

Oregon Health & Science University

International Classification:

C12Q001/70
C07H021/04
C12N007/00
C12N015/86
C12N005/06

US Classification:

435/005000, 435/069300, 435/235100, 435/456000, 435/364000, 530/350000, 536/023720

Abstract:

Japanese macaques can harbor a virus related to RRV, called Japanese macaque herpesvirus (JMHV). An isolated virus is disclosed herein (Japanese macaque herpesvirus, JMHV) as deposited with ATCC as Deposit Accession No. PTA-1884, deposited May 18, 2000, as are viral particles including this virus and host cells infected with this virus. The entire nucleic acids sequence of this virus is provided herein. Also disclosed are the nucleic acid sequences of unique open reading frames, and the polypeptide sequences encoded by these open reading frames. Pharmaceutical compositions are also disclosed that include the viral nucleic acid, a polypeptide encoded by the viral nucleic acid, an antibody that binds the JMHV polypeptide, or a polynucleotide encoding at least one JMHV polypeptide. Model systems for screening for agents of use in the treatment of MS are also disclosed.

US Patent:

20130136768, May 30, 2013

Filed:

Nov 14, 2012

Appl. No.:

13/694280

Inventors:

Jay A. Nelson - Lake Oswego OR, US
Klaus Frueh - Portland OR, US
Michael A. Jarvis - Portland OR, US
Scott G. Hansen - Portland OR, US

Assignee:

Oregon Health & Science University - Portland OR

International Classification:

C12N 15/869
A61K 39/08
A61K 39/00
A61K 39/12
A61K 39/275
A61K 39/21
A61K 39/13
A61K 39/145

US Classification:

4241991, 4353201

Abstract:

Described herein are recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens. The recombinant vectors elicit and maintain high level cellular and humoral immune responses specific for the heterologous antigen. The recombinant RhCMV and HCMV vectors may be used, for example, for the treatment or prevention of infectious disease or cancer. In some examples, the recombinant RhCMV or HCMV vectors may include deletions in genes encoding immunomodulatory proteins. In some examples, the recombinant RhCMV or HCMV vectors may be deficient or impaired in their ability to replicate within a cell, disseminate within the host or spread among hosts by including a deletion in one or more genes essential or augmenting for CMV replication, dissemination or spread.

US Patent:

20130142823, Jun 6, 2013

Filed:

Sep 25, 2012

Appl. No.:

13/626398

Inventors:

OREGON HEALTH AND SCIENCE UNIVERSITY - Portland OR, US
Klaus Frueh - Portland OR, US
Scott G. Hansen - Portland OR, US
Colin Powers - San Diego CA, US

Assignee:

OREGON HEALTH AND SCIENCE UNIVERSITY - Portland OR

International Classification:

A61K 39/245
A61K 39/00
A61K 39/02
C12Q 1/02
A61K 39/12

US Classification:

4241991, 435 5

Abstract:

This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.

US Patent:

20220307054, Sep 29, 2022

Filed:

Aug 19, 2020

Appl. No.:

17/636506

Inventors:

- Portland OR, US
Scott G. HANSEN - Portland OR, US
Daniel MALOULI - Hillsboro OR, US
Louis J. PICKER - Portland OR, US

International Classification:

C12N 15/86
C12N 5/0783
C07K 14/005
C07K 16/28
A61P 31/18
A61P 37/02

Abstract:

The disclosure relates to methods of modulating T cell responses by UL18 of human cytomegalovirus. The disclosure also relates to methods of generating MHC-Ia, MHC-II, and/or MHC-E restricted CD8+ T cells.

US Patent:

20220257740, Aug 18, 2022

Filed:

Jun 5, 2020

Appl. No.:

17/616941

Inventors:

- Portland OR, US
Scott G. HANSEN - Portland OR, US
Louis J. PICKER - Portland OR, US

International Classification:

A61K 39/00
A61K 9/00
A61P 35/00

Abstract:

The present disclosure relates to antigens and methods of generating an immune response for the treatment of cancer. The disclosure also relates to methods of generating MHC-Ia, MHC-II, and/or MHC-E restricted CD8+ T cells for the treatment or prevention of cancer.

US Patent:

20220257748, Aug 18, 2022

Filed:

Jun 5, 2020

Appl. No.:

17/616939

Inventors:

- Portland OR, US
Louis J. PICKER - Portland OR, US
Benjamin J. BURWITZ - Portland OR, US
Scott G. HANSEN - Portland OR, US
Jonah B. SACHA - Beaverton OR, US

International Classification:

A61K 39/12
A61P 31/12
A61K 39/00
A61K 47/30

Abstract:

The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and/or MHC-II restricted CD8 T cells for the treatment or prevention of hepatitis B virus infection.

US Patent:

20210395771, Dec 23, 2021

Filed:

Jul 21, 2020

Appl. No.:

16/934495

Inventors:

- Portland OR, US
Klaus FRÜH - Portland OR, US
Scott G. Hansen - Portland OR, US

International Classification:

C12N 15/86
A61K 39/12
C12N 7/00

Abstract:

Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US11 glycoprotein or a homolog thereof.

US Patent:

20200392534, Dec 17, 2020

Filed:

Jan 9, 2020

Appl. No.:

16/738178

Inventors:

- Portland OR, US
Louis PICKER - Portland OR, US
Scott HANSEN - Portland OR, US
Jonah SACHA - Beaverton OR, US
Daniel MALOULI - Hillsboro OR, US

International Classification:

C12N 15/86
C12N 9/02
C12Q 1/68
C12N 15/00
A61K 39/12
A61K 35/17
A61K 39/21
A61K 39/245
C12N 7/00

Abstract:

Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.